文献速递乳腺MR

酰胺质子转移加权化学交换饱和转移MRI评估三阴性乳腺癌新辅助系统治疗早期反应:一项初步研究

Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transfer-weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study.
PubMed 文献 · Radiol Imaging Cancer · 2021-01-01

这项前瞻性初步研究纳入51例三阴性乳腺癌患者,在NAST基线、2周期后和4周期后行APTW CEST MRI(0.9和2.0 µT饱和功率),采用MTRasym和洛伦兹线形拟合分析。结果显示APTW CEST信号在治疗期间显著下降,但未能区分pCR与非pCR患者。

要点

  • APTW CEST信号在NAST期间显著下降,但pCR与非pCR间无显著差异。
  • 0.9 µT饱和功率联合洛伦兹线形拟合时,pCR患者C2信号较基线显著降低。
  • APTW CEST定量依赖于饱和功率和分析方法的优化。

局限性

  • 初步研究,样本量有限(51例,其中26例有病理反应评估)。
  • 单中心前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To determine if amide proton transfer-weighted chemical exchange saturation transfer (APTW CEST) MRI is useful in the early assessment of treatment response in persons with triple-negative breast cancer (TNBC). Materials and Methods In this prospective study, a total of 51 participants (mean age, 51 years [range, 26-79 years]) with TNBC were included who underwent APTW CEST MRI with 0.9- and 2.0-µT saturation power performed at baseline, after two cycles (C2), and after four cycles (C4) of neoadjuvant systemic therapy (NAST). Imaging was performed between January 31, 2019, and November 11, 2019, and was a part of a clinical trial (registry number NCT02744053). CEST MR images were analyzed using two methods-magnetic transfer ratio asymmetry (MTRasym) and Lorentzian line shape fitting. The APTW CEST signals at baseline, C2, and C4 were compared for 51 participants to evaluate the saturation power levels and analysis methods. The APTW CEST signals and their changes during NAST were then compared for the 26 participants with pathology reports for treatment response assessment. Results A significant APTW CEST signal decrease was observed during NAST when acquisition at 0.9-µT saturation power was paired with Lorentzian line shape fitting analysis and when the acquisition at 2.0 µT was paired with MTRasym analysis. Using 0.9-µT saturation power and Lorentzian line shape fitting, the APTW CEST signal at C2 was significantly different from baseline in participants with pathologic complete response (pCR) (3.19% vs 2.43%; P = .03) but not with non-pCR (2.76% vs 2.50%; P > .05). The APTW CEST signal change was not significant between pCR and non-pCR at all time points. Conclusion Quantitative APTW CEST MRI depended on optimizing acquisition saturation powers and analysis methods. APTW CEST MRI monitored treatment effects but did not differentiate participants with TNBC who had pCR from those with non-pCR. © RSNA, 2021 Clinical trial registration no. NCT02744053 Supplemental material is available for this article.Keywords Molecular Imaging-Cancer, Molecular Imaging-Clinical Translation, MR-Imaging, Breast, Technical Aspects, Tumor Response, Technology Assessment.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Zhang S, Rauch GM, Adrada BE, et al. Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transfer-weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study. Radiol Imaging Cancer. 2021. PMID: 34477453. doi:10.1148/rycan.2021200155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。